Monjuvi (tafasitamab-cxix) / Incyte |
| Completed | N/A | 490 | Europe, US | | MorphoSys AG | Diffuse Large B Cell Lymphoma | 08/19 | 08/20 | | |
NCT04300803: Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL |
|
|
| Approved for marketing | N/A | | NA | Tafasitamab, 12 mg/kg. 4 week cycles: weekly (Cycle 1-3) to bi-weekly (Cycle 4 onwards), loading dose Cycle 1, day 4. Cycle 4 onwards day 1, day 15 until disease progression | MorphoSys AG, Clinigen Healthcare Ltd | DLBCL | | | | |
| Completed | N/A | 3573 | Europe, Canada, US, RoW | | MorphoSys AG | Diffuse Large B Cell Lymphoma | 05/21 | 05/21 | | |
|
NCT06299553: Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND) |
|
|
| Recruiting | N/A | 200 | Europe | | Incyte Biosciences Italy S.r.l, Advice Pharma Group srl | DLBCL - Diffuse Large B Cell Lymphoma | 06/25 | 06/27 | | |
NCT05883709: A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL |
|
|
| Not yet recruiting | N/A | 15 | RoW | Tafasitamab Injection, lenalidomide | Zhao Weili | Diffuse Large B-cell Lymphoma | 12/23 | 12/24 | | |
realMIND, NCT04981795: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL |
|
|
| Recruiting | N/A | 100 | US | Tafasitamab | Incyte Corporation, Iqvia Pty Ltd | Diffuse Large B-cell Lymphoma | 10/25 | 08/26 | | |